Galectin Therapeutics (GALT) Competitors $1.34 +0.02 (+1.52%) As of 12:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. IVA, PHAT, AURA, TRDA, TKNO, OLMA, CMPX, RCKT, HRTX, and ACBShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Inventiva (IVA), Phathom Pharmaceuticals (PHAT), Aura Biosciences (AURA), Entrada Therapeutics (TRDA), Alpha Teknova (TKNO), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Inventiva Phathom Pharmaceuticals Aura Biosciences Entrada Therapeutics Alpha Teknova Olema Pharmaceuticals Compass Therapeutics Rocket Pharmaceuticals Heron Therapeutics Aurora Cannabis Inventiva (NASDAQ:IVA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do analysts prefer IVA or GALT? Inventiva presently has a consensus target price of $10.40, indicating a potential upside of 204.09%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 720.90%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor IVA or GALT? Galectin Therapeutics received 323 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 58.91% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2482.76% Underperform Votes517.24%Galectin TherapeuticsOutperform Votes34758.91% Underperform Votes24241.09% Do insiders and institutionals hold more shares of IVA or GALT? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, IVA or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.20M35.57-$119.51MN/AN/AGalectin TherapeuticsN/AN/A-$41.07M-$0.72-1.86 Which has more volatility and risk, IVA or GALT? Inventiva has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Does the media prefer IVA or GALT? In the previous week, Inventiva had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.62 beat Inventiva's score of 0.48 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IVA or GALT more profitable? Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Galectin Therapeutics N/A N/A -163.15% SummaryInventiva beats Galectin Therapeutics on 8 of the 13 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.81M$6.92B$5.60B$8.61BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.848.8427.2219.97Price / SalesN/A255.17408.95152.58Price / CashN/A65.8538.2534.64Price / Book-1.336.587.114.68Net Income-$41.07M$144.20M$3.24B$248.05M7 Day Performance3.08%3.32%2.47%2.40%1 Month Performance-3.60%10.53%8.66%6.14%1 Year Performance-50.92%3.63%31.22%13.62% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.1935 of 5 stars$1.34+1.5%$11.00+720.9%-49.6%$84.81MN/A-1.849News CoverageGap UpIVAInventiva2.1397 of 5 stars$3.39flat$10.40+206.8%+8.3%$324.29M$9.20M0.00100News CoverageGap DownPHATPhathom Pharmaceuticals4.0856 of 5 stars$4.64+9.2%$17.60+279.3%-18.0%$323.94M$81.86M-0.82110Analyst ForecastOptions VolumeGap UpAURAAura Biosciences2.5596 of 5 stars$6.16+5.1%$22.00+257.1%-7.1%$309.66MN/A-3.5650Positive NewsTRDAEntrada Therapeutics2.9241 of 5 stars$8.14+7.1%$25.67+215.3%-49.3%$308.94M$172.22M5.12110Positive NewsTKNOAlpha Teknova2.8142 of 5 stars$5.73-0.7%$8.50+48.3%+233.5%$306.22M$38.25M-7.74240Positive NewsOLMAOlema Pharmaceuticals2.0928 of 5 stars$4.38-17.0%$24.50+459.4%-70.0%$299.68MN/A-2.0070CMPXCompass Therapeutics3.7172 of 5 stars$2.15+2.4%$13.13+510.5%+99.2%$297.31M$850K-5.8120RCKTRocket Pharmaceuticals4.9584 of 5 stars$2.77+10.4%$21.21+665.9%-86.8%$295.80MN/A-1.01240Trending NewsAnalyst RevisionHigh Trading VolumeHRTXHeron Therapeutics4.0283 of 5 stars$1.93+2.7%$5.50+185.0%-43.4%$294.45M$148.52M-10.72300News CoveragePositive NewsAnalyst ForecastAnalyst RevisionACBAurora Cannabis0.3933 of 5 stars$5.21-1.7%N/A+2.4%$292.88M$320.81M104.221,340Upcoming Earnings Related Companies and Tools Related Companies IVA Alternatives PHAT Alternatives AURA Alternatives TRDA Alternatives TKNO Alternatives OLMA Alternatives CMPX Alternatives RCKT Alternatives HRTX Alternatives ACB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
